BioStock: Patient perspective in focus in Abliva’s phase II/III study

Biotech company Abliva is now preparing for the perhaps biggest step in the company's history to date – a pivotal phase II/III study with the main candidate KL1333. When designing the study, the company has worked together with several patient organisations to gain a deeper understanding of the patients’ reality.

Read the article at biostock.se:

https://www.biostock.se/en/2022/11/patient-perspective-in-focus-in-ablivas-phase-ii-iii-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/